Clinical trials
Phase 3 Hyperparathyroidism, Secondary trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
40 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 1 |
| 2004 | 1 |
| 2006 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 6 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 30 |
| Terminated | 5 |
| Recruiting | 3 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amgen | 16 |
| Kyowa Kirin Co., Ltd. | 3 |
| AbbVie (prior sponsor, Abbott) | 2 |
| OPKO Health, Inc. | 2 |
| OPKO IP Holdings II, Inc. | 2 |
| Pathalys Pharma | 2 |
| Sanwa Kagaku Kenkyusho Co., Ltd. | 2 |
| AbbVie | 1 |
| Abbott | 1 |
| Chengdu Suncadia Medicine Co., Ltd. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hyperparathyroidism, Secondary | 40 |
| Renal Insufficiency, Chronic | 20 |
| Kidney Failure, Chronic | 9 |
| Hyperparathyroidism | 6 |
| Hypocalcemia | 5 |
| Vitamin D Deficiency | 5 |
| Kidney Diseases | 4 |
| Parathyroid Diseases | 3 |
| Renal Insufficiency | 3 |
| Chronic Kidney Disease-Mineral and Bone Disorder | 1 |
Trials
Showing 26 to 40 of 40. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.